Stockreport

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Redhill Biopharma Ltd. - American Depositary Shares  (RDHL) 
US:NASDAQ Investor Relations: ir.redhillbio.com/investor-relations
PDF Neuroblastoma is rare but is the most common infancy malignancy with a median age of diagnosis of 17 months. In the U.S., it accounts for up to around 10% of all childho [Read more]